Drug profile · INN
diroximel fumarate
VUMERITY
diroximel fumarate (VUMERITY) is a kelch-like ech-associated protein 1 inhibitor. Associated with Biogen. Route of administration: oral. Current US regulatory status: approved.
Drug details — diroximel fumarate
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
diroximel fumarate (VUMERITY) is a kelch-like ech-associated protein 1 inhibitor. Associated with Biogen. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Kelch-like ECH-associated protein 1 inhibitor
Primary target: Kelch-like ECH-associated protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is diroximel fumarate?
diroximel fumarate (VUMERITY) is a kelch-like ech-associated protein 1 inhibitor. Associated with Biogen. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for diroximel fumarate?
VUMERITY is a marketed brand name for diroximel fumarate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of diroximel fumarate?
diroximel fumarate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.